Erythritol may impair cellular functions essential to maintaining brain blood vessel health, according to researchers at the ...

F230, originally discovered by Eisai Co., Ltd. and exclusively licensed by GNI Group Ltd. to Gyre, is a fully synthetic small molecule designed to selectively block the ETA receptor. By targeting this ...

Gyre Therapeutics ("Gyre") (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across ...

Travere Therapeutics today announced that the Company will present three abstracts at the upcoming International Podocyte Conference.

Graduates of the Drexel Pathway to Medical School program will achieve eight program level outcomes that describe the skills, competencies and knowledge gained through completion of the program ...

Substantial combination benefit of targeting both the ANGPT2 and VEGFA pathways has been demonstrated preclinically. Angiopoietins (ANGPTs) are ligands of the endothelial cell receptor TIE2 and ...

We hypothesized that ET-1–induced PVAT and vascular oxidative stress and inflammation contribute to the progression of atherosclerosis and increased incidence of AAAs. To test this hypothesis, we ...

Clinical pharmacology is a branch of biomedical science. It includes drug discovery, the study of the effects of drugs on their targets in living systems and their clinical use, as well as the ...

Last year it was joined by Travere Therapeutics' endothelin antagonist Filspari (sparsentan) and a few weeks ago by Novartis' oral complement factor B inhibitor Fabhalta (iptacopan). Meanwhile ...

1 Department of Cell Systems and Anatomy, The University of Texas Health San Antonio, San Antonio, TX, United States 2 Department of Obstetrics, The Second Xiangya Hospital, Central South University, ...